Zandelisib (Synonyms: ME-401; PWT-143) |
| Catalog No.GC62480 |
Zandelisib (ME-401) es un inhibidor de fosfatidilinositol 3-quinasa (PI3K) extraÍdo de la patente WO2019183226 A1, Ejemplo de compuesto 1. Zandelisib inhibe selectivamente p110δ con una IC50 de 3,5 nM. Zandelisib funciona como un antineoplÁsico.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1401436-95-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC50 of 3.5 nM. Zandelisib functions as an antineoplastic[1][2].
Zandelisib inhibits PI3Ks with IC50s of 4, 976 nM, 605 nM, 817 nM and 3.5 nM for p110α, p110β, p110γ and p110δ, respectivey[1].
[1]. Daniel P. Gold, et al. Combination therapy. WO2019183226A1.
[2]. David Brown, et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1.
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *